| (Unaudited, in millions, except per share data, and Doctor counts) | ||||||||||||||||||
| Three Months Ended | ||||||||||||||||||
| 2026 | 2025 | Change | ||||||||||||||||
| Revenue | 6.2% | |||||||||||||||||
| Gross Margin | (35.3%) | |||||||||||||||||
| Gross Margin percentage | 10.2% | 16.7% | (650 bps) | |||||||||||||||
| Net Income (Loss) | ( | (124.9%) | ||||||||||||||||
| Diluted EPS | ( | ( | ||||||||||||||||
| Adjusted Gross Margin(a) | 2.6% | |||||||||||||||||
| Adjusted Gross Margin Percentage(a) | 19.5% | 20.2% | (70 bps) | |||||||||||||||
| Adjusted EBITDA(b) | (13.2%) | |||||||||||||||||
| Adjusted EBITDA margin(b) | 7.6% | 9.3% | (170 bps) | |||||||||||||||
| Adjusted Diluted EPS(c) | ( | |||||||||||||||||
| Same Practice Revenue Growth | 4.1% | 1.2% | 290 bps | |||||||||||||||
| Practicing Affiliated Doctors | 221 | 203 | 8.9% | |||||||||||||||
(a) See Non GAAP Reconciliation of Gross Margin to Adjusted Gross Margin below
(b) See Non GAAP Reconciliation of Net Income (Loss) to Adjusted EBITDA below
(c) See Non GAAP Reconciliation of Earnings (Loss) Per Share to Adjusted Earnings Per Share below
Executive Commentary –
“We delivered a solid start to 2026, with revenue increasing 6.2% year over year, driven by strong same practice performance and continued patient demand. Results were consistent with our expectations and reflect continued execution against our operating plan. We continue to invest in recruiting, staffing, and clinical capacity to support long-term growth.
With strong liquidity and a flexible balance sheet, we remain well positioned to execute on our growth strategy, including expanding current practices and adding new practices through disciplined acquisitions and de novo expansion.”
Financial Results – First Quarter 2026
- Revenue increased 6.2% over the prior year’s comparable quarter to
$62.7 million , due to increased patient visits and growth in clinical hours, the impact of acquisitions and reimbursement growth. Same practice revenue growth was 4.1%. Revenue from acquisitions in the past 12 months contributed approximately$0.8 million in the quarter. - Total General Practice revenue grew 6.4% over the prior year’s comparable quarter to
$46.1 million . Total Multi-Specialty Practice revenue grew 5.7% to$16.6 million . - Cost of services was
$56.3 million , an increase of$7.1 million above the prior year’s comparable quarter, driven primarily by share-based compensation recorded in the quarter and growth in doctors and team members. - General and administrative costs were
$7.8 million , an increase of$0.9 million above the prior year’s comparable quarter. The primary driver of these increases was share-based compensation, acquisition-related costs, and public company costs, net of lower IPO preparation costs related to our 2025 offering. - Net loss was
$(0.4) million , compared to net income of$1.6 million in the prior year comparable quarter, primarily driven by increased salaries and benefits, and share-based compensation, partially offset by revenue growth, tax benefits on share-based compensation, and operating leverage. - Adjusted EBITDA was
$4.7 million , or 7.6% of revenue, compared to$5.5 million , or 9.3% of revenue in the prior year comparable quarter. - Adjusted diluted earnings per share were
$0.44 versus$1.14 in the prior year’s comparable quarter, due primarily to the increase in shares issued and vested during the IPO.
Affiliated Practice Updates
- As of
March 31, 2026 , we supported 86 affiliated practices and 221 affiliated doctors. - First quarter patient retention rate was 90.1%.
- Patient visits increased to 178,527 across our affiliated dental practices.
- During the first quarter our affiliated dental practices completed one general practice acquisition in
Tucson, Arizona , as previously announced onJanuary 23, 2026 . The acquired practices’ impact on revenues and net earnings was not material for the quarter.
Balance Sheet, Liquidity, and Cash Flow
- Cash and cash equivalents were
$24.4 million as ofMarch 31, 2026 . - Total debt outstanding was approximately
$11.5 million as ofMarch 31, 2026 , and our$15 million line of credit was undrawn at quarter end. - Total shares outstanding were 4.5 million shares as of the end of the quarter.
- We generated
$5.0 million in operating cash flow in the first quarter, a decrease of$0.8 million compared to the prior year comparable quarter due primarily to changes in working capital. - First quarter capital investments were
$2.3 million .
Full-Year 2026 Outlook
First quarter results were consistent with our expectations, and we are maintaining our fiscal 2026 outlook range. Our outlook excludes the impact of any future practice affiliations or acquisitions that have not yet closed. As a result, actual results may differ materially depending on the timing and number of future affiliations, de novo practice openings, or acquisitions completed during the year.
| Year Ending | Year Ended | Percent | ||||||
| Change | ||||||||
| ($ in millions) | (Outlook) | (Actual) | (At Midpoint) | |||||
| Revenue | 4.7% | |||||||
| Adjusted EBITDA | - | |||||||
| Adjusted EBITDA margin | 8.3% - 8.9% | 9.0% | ||||||
Our outlook includes 3.5% to 5.0% same practice revenue growth and approximately
Conference Call
As announced on
A live webcast of the call will be accessible by registering using the link below or through the Investor Relations section of the Company’s website at https://investors.parkdentalpartners.com. A replay of the webcast will be available on the website for a limited time following the call.
About
Basis of Consolidation
In accordance with generally accepted accounting principles in
Forward Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company’s financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include those preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” or similar expressions. These forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by such forward-looking statements because of, among other things, potential risks and uncertainties, such as:
- Regulatory and compliance risk, including state dental corporate practice of dentistry and fee-splitting restrictions, HIPAA and other privacy/cybersecurity obligations, and evolving healthcare and labor regulations;
- Reimbursement risk, including risks related to payer mix, reimbursement rates, audit/recoupment activity, enrollment and collections timing, and dependence on significant third-party payors;
- Our ability to identify, acquire, integrate and effectively support affiliated practices and to execute de novo expansion, and the risk of undiscovered liabilities in acquisitions;
- Dependence on affiliated dental practices and their clinical performance; our ability to attract, hire and retain dentists, specialists and hygienists; and risks related to ownership transitions of affiliated entities;
- Competition for patients and clinicians in our markets and the impact on patient volumes and staffing;
- Macroeconomic conditions, inflation and interest rates, and our geographic concentration, particularly in the markets we operate.
A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. We are under no obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether because of new information, future events or otherwise.
Non-GAAP Financial Measures
This news release and the related conference call include presentation of Non-GAAP measures that include or exclude special items of a nonrecurring and/or nonoperational nature. Management believes that the Non-GAAP measures provide useful information to investors regarding the Company’s results of operations and financial condition because they permit a more meaningful comparison and understanding of
Please note that the Company has not provided the most directly comparable GAAP financial measure, or a quantitative reconciliation thereto, for the Adjusted EBITDA forward-looking guidance for 2026 included in this press release in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. Providing the most directly comparable GAAP financial measure, or a quantitative reconciliation thereto, cannot be done without unreasonable effort due to the inherent uncertainty and difficulty in predicting certain non-cash, material and/or non-recurring expenses or benefits; legal settlements or other matters; and certain tax positions. The variability of these items could have an unpredictable, and potentially significant, impact on our future GAAP financial results.
See Supplemental non-GAAP financial tables below for a reconciliation of adjusted non-GAAP financial measures to GAAP.
Supplemental Financial Tables
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) | |||||||||
| (in thousands, except share and per share amounts) | |||||||||
| Three Months Ended | |||||||||
| 2026 | 2025 | ||||||||
| REVENUE | $ | 62,695 | $ | 59,037 | |||||
| COST OF SERVICES | |||||||||
| Salaries and benefits | 41,895 | 35,637 | |||||||
| Dental supplies and Laboratory fees | 4,338 | 4,239 | |||||||
| Office occupancy | 4,285 | 4,004 | |||||||
| Other practice expenses | 3,834 | 3,405 | |||||||
| Depreciation | 1,963 | 1,896 | |||||||
| TOTAL COST OF SERVICES | 56,315 | 49,181 | |||||||
| GROSS MARGIN | 6,380 | 9,856 | |||||||
| General and administrative expenses | 7,840 | 6,928 | |||||||
| Depreciation and amortization | 420 | 378 | |||||||
| OPERATING INCOME (LOSS) | (1,880 | ) | 2,550 | ||||||
| INTEREST EXPENSE - NET | (121 | ) | (337 | ) | |||||
| INCOME (LOSS) BEFORE TAX | (2,001 | ) | 2,213 | ||||||
| PROVISION/(BENEFIT) FOR INCOME TAX | (1,611 | ) | 646 | ||||||
| NET INCOME (LOSS) | $ | (390 | ) | $ | 1,566 | ||||
| EARNINGS (LOSS) PER SHARE: | |||||||||
| Basic | $ | (0.09 | ) | $ | 0.88 | ||||
| Diluted | $ | (0.09 | ) | $ | 0.88 | ||||
| Basic weighted-average number of common shares outstanding | 4,383,073 | 1,783,352 | |||||||
| Diluted weighted-average number of common shares outstanding | 4,383,073 | 1,783,352 | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEET (unaudited) | |||||||
| (in thousands) | |||||||
| At March 31, | At December 31, | ||||||
| 2026 | 2025 | ||||||
| ASSETS | |||||||
| Cash and cash equivalents | $ | 24,372 | $ | 25,185 | |||
| Accounts receivable?–?net of allowance | 6,819 | 6,991 | |||||
| Other current assets | 6,531 | 5,726 | |||||
| Total current assets | 37,722 | 37,902 | |||||
| OTHER ASSETS: | |||||||
| Property and equipment and lease assets | 73,945 | 73,828 | |||||
| 29,793 | 28,360 | ||||||
| Other assets | 38,397 | 38,093 | |||||
| Total other assets | 142,135 | 140,281 | |||||
| TOTAL ASSETS | $ | 179,857 | $ | 178,183 | |||
| LIABILITIES AND DEFICIT | |||||||
| Accounts payable and other accrued liabilities | $ | 6,682 | $ | 6,291 | |||
| Payroll, benefits and short term deferred compensation | 16,802 | 16,716 | |||||
| Current portion of debt and lease liabilities | 8,730 | 8,606 | |||||
| Deferred Revenue and other current liabilities | 3,084 | 4,120 | |||||
| Total current liabilities | 35,298 | 35,733 | |||||
| LONG-TERM LIABILITIES: | |||||||
| Deferred compensation | 67,569 | 68,417 | |||||
| Long-term debt and lease liabilities | 51,016 | 51,744 | |||||
| Other long-term liabilities | 537 | 486 | |||||
| Total long-term liabilities | 119,122 | 120,647 | |||||
| TOTAL LIABILITIES | $ | 154,420 | $ | 156,380 | |||
| Total shareholders’ equity | $ | 25,437 | $ | 21,803 | |||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 179,857 | $ | 178,183 | |||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) | ||||||||
| (in thousands) | ||||||||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income (loss) | $ | (390 | ) | $ | 1,566 | |||
| Adjustments to reconcile net income (loss) to net cash flows from operating activities: | ||||||||
| Depreciation and amortization | 2,383 | 2,274 | ||||||
| Deferred income taxes | (470 | ) | — | |||||
| Change in cash surrender value of life insurance | 440 | 335 | ||||||
| Noncash lease and loss on disposal of equipment | 31 | (15 | ) | |||||
| Share based compensation | 4,024 | — | ||||||
| Changes in operating assets and liabilities | (992 | ) | 1,699 | |||||
| Net cash flows from operating activities | 5,026 | 5,859 | ||||||
| NET CASH FLOWS USED IN INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | $ | (2,305 | ) | $ | (2,420 | ) | ||
| Life insurance premiums paid | (273 | ) | (664 | ) | ||||
| Payments for purchases of dental practices | (1,595 | ) | — | |||||
| Issuance of notes to related parties | (600 | ) | — | |||||
| Net cash flows used in investing activities | (4,773 | ) | (3,084 | ) | ||||
| CASH FLOWS USED IN FINANCING ACTIVITIES: | ||||||||
| Dental practice purchase installment payments | $ | (8 | ) | $ | (8 | ) | ||
| Net change in checks issued in excess of cash balances | (573 | ) | (1,328 | ) | ||||
| Net proceeds (payments) on debt and capital leases | (485 | ) | (489 | ) | ||||
| Cash paid for Share Repurchase | — | (154 | ) | |||||
| Net cash flows used in financing activities | (1,066 | ) | (1,979 | ) | ||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (813 | ) | 796 | |||||
| CASH AND CASH EQUIVALENTS – Beginning of year | 25,185 | 2,672 | ||||||
| CASH AND CASH EQUIVALENTS - End of year | $ | 24,372 | $ | 3,468 | ||||
| RECONCILIATION OF GROSS MARGIN TO ADJUSTED GROSS MARGIN (unaudited) | |||||||||||||
| (in thousands) | |||||||||||||
| Three Months Ended | |||||||||||||
| 2026 | 2025 | ||||||||||||
| GROSS MARGIN | $ | 6,380 | 10.2 | % | $ | 9,856 | 16.7 | % | |||||
| Addback: | |||||||||||||
| Share based compensation | 3,665 | 5.8 | % | - | 0.0 | % | |||||||
| Restructuring costs1 | 37 | 0.1 | % | 63 | 0.1 | % | |||||||
| Deferred compensation | 160 | 0.3 | % | 85 | 0.1 | % | |||||||
| Depreciation | 1,963 | 3.1 | % | 1,896 | 3.2 | % | |||||||
| ADJUSTED GROSS MARGIN | $ | 12,205 | $ | 11,900 | |||||||||
| ADJUSTED GROSS MARGIN PERCENTAGE | 19.5 | % | 20.2 | % | |||||||||
| 1 Restructuring costs primarily consist of expenses incurred in connection with the Company’s initial public offering. | |||||||||||||
| RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (unaudited) | |||||||||||||
| (in thousands) | |||||||||||||
| For the Three Months Ended | |||||||||||||
| 2026 | 2025 | ||||||||||||
| NET INCOME (LOSS) | $ | (390 | ) | (0.6 | %) | $ | 1,566 | 2.7 | % | ||||
| Addback: | |||||||||||||
| Provision/(Benefit) for income tax | (1,611 | ) | (2.6 | %) | 646 | 1.1 | % | ||||||
| Interest expense, net | 121 | 0.2 | % | 337 | 0.6 | % | |||||||
| Depreciation and amortization | 2,383 | 3.8 | % | 2,274 | 3.9 | % | |||||||
| EBITDA | $ | 503 | 0.8 | % | $ | 4,823 | 8.2 | % | |||||
| Adjustments: | |||||||||||||
| Share based compensation | 4,024 | 6.4 | % | - | 0.0 | % | |||||||
| Restructuring costs1 | 58 | 0.1 | % | 557 | 0.9 | % | |||||||
| Deferred compensation | 160 | 0.3 | % | 85 | 0.1 | % | |||||||
| ADJUSTED EBITDA | $ | 4,745 | 7.6 | % | $ | 5,465 | 9.3 | % | |||||
| 1 Restructuring costs primarily consist of expenses incurred in connection with the Company’s initial public offering. | |||||||||||||
| RECONCILIATION OF EARNINGS (LOSS) PER SHARE TO ADJUSTED EARNINGS PER SHARE (unaudited) | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| EARNINGS (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS: | $ | (390 | ) | $ | 1,566 | |||
| Adjustments: | ||||||||
| Share based compensation | 4,024 | - | ||||||
| Restructuring costs | 58 | 557 | ||||||
| Deferred compensation | 160 | 85 | ||||||
| Income tax effect of the Adjustments1 | (1,188 | ) | (180 | ) | ||||
| ADJUSTED NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ | 2,664 | $ | 2,028 | ||||
| Adjusted Weighted Average Diluted Shares - Reconciliation | ||||||||
| WEIGHTED-AVERAGE SHARES USED IN COMPUTING GAAP NET LOSS PER SHARE, DILUTED | 4,383,073 | 1,783,352 | ||||||
| ADJUSTED WEIGHTED AVERAGE DILUTED SHARES USED IN COMPUTING ADJUSTED EARNINGS PER SHARE, DILUTED2 | 6,059,839 | 1,783,352 | ||||||
| ADJUSTED DILUTED EARNINGS PER SHARE: | $ | 0.44 | $ | 1.14 | ||||
| 1 Income tax effect is based on an estimated long-term annual effective tax rate of 28% tax rate for the three months ended | ||||||||
| 2 Includes an additional 1,584,666 of weighted average dilutive shares and 92,100 of weighted average dilutive warrants for the three months ended | ||||||||
| CONSOLIDATED OPERATING METRICS (unaudited) | |||||||
| For the Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Patient Visits1 | 178,527 | 175,940 | |||||
| Same Practice Revenue Growth2 | 4.1% | 1.2% | |||||
| Patient Retention Rate3 | 90.1% | 89.2% | |||||
| Doctor Count4 | 221 | 203 | |||||
| 1 A patient visit is counted when service is provided to a patient at one of our affiliated dental general dentistry practices. Measuring the year-over-year change in patient visits helps us to evaluate how the affiliated dental practices are performing. It also helps with evaluating demand for services which influences decision-making relating to matters such as appropriate staffing levels and recruiting needs. In addition, it influences decision-making processes relating to our marketing, sales and advertising strategies and helps us with evaluating the effectiveness of those strategies. Further, with respect to continuing care patient count, it allows us to evaluate the ability of affiliated dentists to encourage patients to complete their diagnosed dental treatment plans. |
| 2 Same practice revenues represent total revenues for same dental practice locations that have been operating for at least 13 full months prior to the end of a given reporting period and which have not been closed, or sold during such period. Measuring the year-over-year change in same practice revenues allows us to evaluate how affiliated dental practices are performing. We believe various factors affect comparable practice revenues, including patient demand for dental services, economic trends, dentist and hygienist staffing levels, availability of dentists and hygienists, pricing, competition, visibility and accessibility of the dental practices, quality of the tenants surrounding the dental practices, clinical hours and the level of patient service provided inside and outside of the dental practices. |
| 3 Patient retention rate is calculated by counting patients that remain active at the beginning and end of a twelve-month period. Active patients are defined as general dentistry patients having been seen by our affiliated dental practices within the past 36 months, or last 18 months for patients under the age of 18. Patients who have not been seen by our affiliated dental practices within these time periods are removed from our active patient lists. This methodology is aligned with |
| 4 Dentists operating in one of our affiliated dental practices are included in this calculation, which includes both full and part-time dentists. Measuring the year-over-year and quarter-over- quarter change in dentist count allows us to evaluate the production capacity of affiliated dental practices. It also influences decision-making relating to matters such as appropriate staffing levels and recruiting needs. |

Company Contact InformationInvestor Contact:Park Dental Partners Investor Relations Team763-233-3377ir@parkdentalpartners.comMedia Contact:Park Dental Partners Media Relations Team651-633-0500marketing@parkdentalpartners.comSource:
